European Psychiatry - Volume 33 - March 2016

159 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S155
Methods Fifty-eight outpatients with stable SCZ completed the
intention-inferencing task (IIT), in which the ability to infer a char-
acter’s intentions from28 short comic strip stories is assessed. They
also completed a neuro-cognitive battery comprising the following
tests: the Hopkins Verbal Learning Test–Revised (HVLT-R), the Let-
ter Digit Substitution Test (LDST), the Stroop Test (ST), the “Double
Barrage” of Zazzo (DBZ), the Modified Card Sorting Test (MCST),
Verbal Fluency (VF), the Trail Making Test-Part A (TMT-A) and the
Digit Span (DS).
Results The performance in the IIT significantly correlated with
performance in some neuro-cognitive tests including efficiency in
DBZ, number of uncorrected mistakes in ST, number of correct cat-
egories in MCST and the time needed to succeed the TMT-A. No
correlations were found between performance in the ITT and in
memory tasks (HVLT-R and DS).
Conclusions ToM may rely on some neuro-cognitive functions
(mainly attention and executive functioning). Elucidating the exact
relationship between ToM and NF may be useful as both are tar-
geted in specific psychotherapeutic interventions.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW115
Cognitive, anxiety and depressive
disorders in middelage subjects with
metabolic syndrome are associated
with elevated endocannabinoid
plasma level
V. Piotrovskaya ∗, N. Neznanov
First State Pavlov Medical University, Psychiatry, St. Petersburg,
Russia
∗ Corresponding author.
Obesity and metabolic syndrome (MS) are associated with an
increased risk of developing psychiatric disorders, such as mood
disorders and cognitive disorders. Endocannabinoids (EC) are
neuromodulators which are involved in a plenty of physio-
logical processes: regulation of motor activity, neuroprotection,
modulation of immune function and inflammatory responses,
antiproliferative actions in tumoral cells, control appetite. Endoge-
nous cannabinoids playmodulatory role in cognitive and emotional
processes (1).
Aim of this study was to evaluate a possible association
between EC plasma levels, such as anandamide (AEA) and
2-arachidonoylglycerol (2-AG), and mental processes such as, cog-
nitive impairment and anxiety in obesity. And thus determine the
participation of the EC system in the development of cognitive and
emotional disorders with obesity.
Methods and results Data analyzed from 271 patients with MS
according IDF criteria (aged 30–60 years). Current mild cognitive
impairment (MCI), depressive (D) and anxiety disorders (A) were
confirmed by psychodiagnostic interview according to the criteria
of ICD-10. All patients passed through: MMSE test, scales HADS,
HARS, HAM-A. Determining the ES level (anandamide, 2-AG) by
liquid chromatography. Subjects were divided into 2 groups, group
A – withDand/or A (139) and groupB – without affective disorders
(132). Using Mann-Whitney test significant connection between
high levels of 2-AG level and affective disorders in group A were
obtained. Subjects with D and A and MCI had higher level of 2-AG
and AEA in comparison with only MCI.
Conclusion Increased levels of 2-AG and AEA provoke comorbid-
ity of MCI depression and anxiety.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW116
Neurocognitive and functional
performance in psychotic and
non-psychotic bipolar patients and
schizophrenia patients
A. Aparicio ∗, E.M. Sánchez-Morla , J.L. Santos
1 University of Castilla La Mancha, School of Nursery, Cuenca, Spain
2 University of Alcalá, School of Medicine, Psychiatry, Alcalá de
Henares, Spain
3 Hospital Virgen de La Luz, Psychiatry, Cuenca, Spain
∗ Corresponding author.
Introduction It has been suggested that psychotic bipolar patients
havemore severe cognitive deficits and lower functioning that non-
psychotic bipolar patients.
Objectives To evaluate neurocognitive and functional perfor-
mance in stabilized psychotic bipolar patients (BP+), non-psychotic
bipolar patients (BP−) and schizophrenia patients (SZ).
Aims To examine whether BP+ might be defined as a more
homogenous subtype of bipolar disorder with more severe cog-
nitive deficit and more severe functional impairment.
Methods Fifty TB+, 50 TB−, 50 SZ and 51 controls were eval-
uated with a comprehensive neurocognitive battery (WCST, FAS,
TMT-A and B, Stroop Test, Digits span, letters and numbers –
WMS-III−, CVLT, ROCFT, CPT-DS). Moreover, patients were eval-
uated with clinical scales (PANSS, MADRS, YMRS) and functionality
scales (WHOs Disability Assessment Scales, QLS and GAF). IBMSPSS
Statistics (version 19.0) was used to the data analysis.
Results No significant differences were found between three
patients’ samples (P < 0.0001). No significant differences in neu-
rocognitivemeasureswere found between BP+ and BP−. Significant
differenceswere found betweenboth groups of bipolar patients and
schizophrenia in working memory measures (P < 0.0001). BP+ and
BP− showed significant higher functionality than SZ (P < 0.0001),
without significant differences in functionality between BP+ and
BP−.
Conclusions The pattern of neurocognitive and functional deficit
is similar in BP+ and BP−. The neurocognitive deficit is very simi-
lar in both groups of bipolar patients groups in comparison to SZ;
functionality is better in both bipolar groups than in schizophrenia
patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW117
Neurocognitive training in the
complex therapy of patients with
schizophrenia
A. Sofronov ∗, A. Spikina
1 Saint Petersburg, Russia
2 North West Medical University named by I.I. Mechnikov,
psychiatry, Saint Petersburg, Russia
∗ Corresponding author.
Neurocognitive deficits in schizophrenia patients is a major health
and social problem of modern psychiatry nowadays. Many patients
with schizophrenia are of working age and there is a high enough
percentage of their disability.
Objective To study the influence of neurocognitive training on
higher cortical functions in schizophrenia patients and to evaluate
their effectiveness in the treatment of schizophrenia.
Material and methods We formed groups of patients diagnosed
with paranoid schizophrenia undergoing treatment in the depart-
ments of rehabilitation and day hospital. Patients of themain group
(102 patients) additionally participated in the training of cognitive
deficits. Patients included in the comparison group (48 patients)
received only pharmacotherapy.